
THIS IS EXPORT. THIS IS WALES.

SAN DIEGO & LOS ANGELES, USA & BIO INTERNATIONAL CONVENTION

Export Market Visit

1 - 7 June 2024

tradeandinvest.wales





This is Export.
This is Wales.

San Diego & Los Angeles, USA

Biofortuna	06
Finalrentals	07
Impervious Waterproofing	08
White Fire Media	09

BIO International Convention

3D Pharma Consulting	11
Aparito	12
Biocatalysts	13
CatSci	14
clear_pixel VR	15
Cotton Mouton Diagnostics	16
Llusern Scientific	17
Sharp Clinical Services (UK)	18
The Science Behind	19
TrakCel	20



Pierhead, Senedd and
Wales Millennium Centre, Cardiff Bay

Wales is a self-governing constituent country of the UK and the Welsh Government is the devolved Government for Wales.

Devolved since 1999, the Welsh Government's decision-making powers within a small and joined-up country mean we can cut red-tape and act fast.

They also mean we are responsible for our own economic development, working with business to create a prosperous, green and equal economy.

Wales has a strong industrial heritage that has shaped our confident, creative and ambitious economy of today. We have strength in depth in advanced manufacturing, creative industries, energy and environment, financial and professional services, food and drink, life sciences, and technology.

Our commitment to sell Wales to the world has never been more focussed and this mission provides an ideal platform for us to build on established links and discuss future export opportunities.

Wales means business.

Biofortuna is a contract assay development and manufacturing organisation providing a flexible and scalable outsourcing service to the sector's leading in-vitro and point-of-care assay developers.



Biofortuna services are wide-ranging, and whether they are supporting diagnostic companies, food safety experts or life science specialists their objectives are the same; to form long term partnerships and become a valued extension of your team.

Biofortuna do that by solving problems and presenting opportunities. They listen to your requirements, develop customised solutions and deliver them with openness and transparency.

Operating from state-of-the art, humidity-controlled premises, and benefiting from ISO 13485 certification, ISO 17025 accreditation and FDA registration, they have a proven track record in the development and large-scale manufacture of diagnostic assays.

Product/Service

Genomic services, RNA/DNA extraction, Cell line authentication, DNA relationship testing, Custom assay development, PCR, Immunoassays, ELISA, LAMP, Lyophilisation, Lyophilised cakes, Lyophilised beads, Contract manufacturing, Dispensing & Kitting and Stability Storage.

Objectives

Biofortuna's objectives are to develop long term partnerships with leading diagnostic developers and enable them to get their assays to market faster and more efficiently.



Paul Williams
Head of Sales

+44 (0)7388 532 771
paul.williams@biofortuna.com

www.biofortuna.com

Finalrentals helps consumers find the best prices for car rentals online while empowering local car rental companies to boost their online presence and gain a wider reach to potential customers without the need to understand the technologies involved.



2022 saw expansion into 14 new countries and 172 new locations and on average each location makes £14 thousand annually through Finalrentals innovative 3-tier technology solution.

Considering how big the car rental market is, the capabilities of Finalrentals as a technology export company has great potential. Based on the customer feedback so far, it is evident that their technology is helping local car rental companies to acquire more customers and become better at technology. The penetration of Finalrentals product proves that the technology meets their customer's needs and requirements.

Product/Service

Car Rental Technology based on Web, Mobile and API.

Objectives

Finalrentals is looking forward to expanding to the United States and is looking forward to meeting local car rental companies for a demo of their platform and marketplace.



Ammar Akhtar
Founder and CEO

+44 (0)7983 590 046
amm@finalrentals.com

www.finalrentals.com

Impervious provide world-leading roofing, waterproofing and associated products for the construction industry.



With roots in the industry for over 35 years, Impervious has been an innovator of polyurethane technology throughout the world. Offering a full range of waterproofing products for new and existing construction projects. These systems can be used on roofs, balconies, car parks, water tanks and more. Our range includes polyurethane membranes, sealants & adhesives, coatings, and cementitious compounds. Technical support and advice are at the forefront of what is offered at Impervious Waterproofing.

Product/Service

IMPETHANE® Liquid Waterproofing Systems

IMPEFLEX Gutter Lining & Patch Repair System

IMPEGLASS Flexible GRP Alternative PU System

IMPETHANE HS Polyurea Systems

IMPECRETE Cementitious Waterproofing Systems

Plus, many more.

Objectives

Introduce the Impervious Range and its innovative technologies to a new and exciting market with the aim of claiming a stake in the Flat Roofing & Waterproofing sectors of the industry.



Owen Morgan
Director

+44 (0)7825 769 390
owen@imperviousw.com

www.imperviousw.com

Negotiated Fast Channel Welsh Wednesdays Deal with Maximum Effort and Ryan Reynolds. Media Consultant for numerous Production, Tech and Digital companies in Wales.



Developing Original Content Ideas across all media and platforms for export to International market. Specialising in New Tech and Content. Representing their ideas, Company information IP and products and delivering Business growth strategy and IP development as well as Commercialisation of IP abroad. Have Content Unscripted and Scripted Content in Development with Netflix and More Better Productions and Maximum Effort. In Discussion about new Content IP with US Distributors and Broadcasters. Already a strong long lasting relationship with US, ambition to strengthen.

Product/Service

Content, Media, Digital, Tech, Production.

Objectives

Networking and pitching of Original IP for numerous production companies,

connecting and Networking for the benefit of Coproduction, Co-development of IP, new Tech and Digital tech with several Welsh companies.



Llinos Griffin-Williams
Director

+44 (0)7792 110 158
llinos@whitefiremedia.co.uk



Growth.

The vibrant capital city of Wales – Cardiff is one of the fastest growing cities in the UK. It is also just two hours on the train from London.

Established by Dr Paul Seaman in 2019, **3D Pharma Consulting Ltd** is based in Cardiff and provides CMC (chemistry, manufacturing and control) support to small and medium sized pharmaceutical companies.



With expertise in the technical, operational and quality elements required for the development of new drugs and technologies, 3D Pharma Consulting works closely with customers' in-house teams to design, execute and manage drug and device development programmes that deliver the required technical outputs and business goals. Complex parenterals and non-standard manufacturing processes are an area of particular expertise. 3D Pharma Consulting Ltd has a broad network of contract manufacturers and will support the selection, set-up and management of drug product supply chain for cost-effective and compliant clinical manufacture.

Product/Service

3D Pharma Consulting Ltd provides development services to companies as they prepare for clinical trials, including:

- Development of drug delivery solutions and formulation
- Manufacturing process development, scale-up & technology transfer
- Regulatory guidance and document preparation
- R&D and manufacturing project management

Objectives

1. Engage with potential customers for 3D Pharma Consulting.
2. Engage manufacturing supply chain partners to further grow the network of CDMOs that 3D Pharma Consulting can work and develop relationships with.
3. Meet with existing customers to reinforce and expand current contracts.



Dr Paul Seaman
Director & Principal Consultant

+44 (0)7515 053 407
paul@3d-pharma.co.uk

www.3d-pharma.co.uk



Aparito digitises clinical trials and accelerates drug development by supporting clinical trials at home or in the clinic with the Atom5™ eCOA platform. This moves from relying on sterile, snapshot assessments to continuous, real-time, real-world data utilising novel eCOA and digital biomarkers.

Product/Service

The Atom5™ platform is Part 11, GDPR and HIPPA compliant and supports clinical trials at scale with video eCOAs, ePROs, Wearables, Telemedicine and eConsent, available in 193 countries and 125 languages.

The platform captures multiple, high-frequency data points from video, voice, wearables and ePRO and analyses the data in conjunction with a team of data scientists to provide rich, real-time insights to clinical teams.

Objectives

Secure 20 meetings with relevant prospects from biotech and pharma companies with rare disease drugs in early-stage development.

Secure 5 meetings with CROs who operate hybrid and decentralised clinical trials.



Dr Elin Haf Davies
Chief Executive Officer

+44 (0)1978 896 191
info@aparito.com

www.aparito.com

Biocatalysts Ltd are a global biotechnology company producing speciality enzymes at commercial scales for a variety of industries, such as food, flavour & fragrance, pharmaceutical, life sciences, fine chemicals and many more.



Our state-of-the-art facility has a vertically integrated manufacturing process that optimises the large-scale production of novel enzymes, fermented proteins, and pharmaceutical biocatalysts.

Product/Service

Biocatalysts Ltd offer enzyme products and a customised enzyme development and manufacturing service.

Biocatalysts Ltd have the tools and flexibility to provide tailored solutions specific to customers' needs and can deliver rapid enzyme scale up from discovery through to full commercialisation.

Biocatalysts Ltd develop and manufacture speciality enzymes for both food and non-food applications. More specifically this can include enzymes for flavour enhancement, improving functionality and digestibility of plant and animal-derived proteins, as well as enzymes used in fundamental molecular biology techniques to advance drug discovery, and modify and manipulate DNA for diagnostic and therapeutic purposes.

Objectives

BIO 2024 provides the opportunity to meet new technology partners to understand the latest industry challenges and how biotechnology and Biocatalysts Ltd.'s experience and knowledge can improve process efficiencies and innovation for new and existing customers.



Daren Bryce
Vice President – Food
& Pharmaceuticals

+44 (0)7973 419 818
daren.bryce@biocatalysts.com

www.biocatalysts.com

Spun out of AstraZeneca in 2010, **CatSci** is a UK-based award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines to patients in need



Bridging the innovation challenge for large pharma and biotech, from small molecules, TACS and glues to oligonucleotides and other complex synthetic medicines, they have been trusted for over a decade to deliver perfect-for-purpose CMC development programmes for customers from across the globe.

Product/Service

CatSci's tailored services include route scouting and selection, initial process scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through their partnership with AGC Pharma Chemicals, they offer scalable small molecule GMP API material supply, from grams to tonnes, with seamless knowledge transfer.

Objectives

CatSci's mission is to meet with new and existing customers to discuss their dynamic portfolio demands and how CatSci's expertise can help them

overcome their project challenges. CatSci's purpose is and always will be to get new medicines to patients in need, working together with innovative pharmaceutical companies to be the leading partner for the development of small molecule and complex medicines using agility to drive speed and expertise to ensure quality.



Dr Simon Tyler
Chief Commercial Officer

+44(0)3300 250 170
+44(0)7875 202 764
simon.tyler@catsci.com

Jas Douville
Head of Business Development
– North America

1 418 955 1368
jas.douville@catsci.com

<https://catsci.com/>

clear_pixel VR recreates laboratory processes, medical procedures and medical equipment in virtual reality.

clear_pixel^{VR}

Product/Service

Their bespoke, high quality and hyper realistic virtual environments offer unrivalled training and showcasing opportunities in a scalable and cost-effective way and are helping to transform the digital health landscape.

For medical professionals and medical organisations, the benefits of clear_pixel VR's virtual reality environments include increased skills, confidence and employee engagement due to unlimited training opportunities on real world procedures and equipment, accessible anytime and from anywhere, and lower training costs due to less reliance on senior staff oversight time, less breakages and lower consumable waste.

For equipment manufacturers, replicating equipment in virtual reality and exactly how it operates means sales teams can sell better, potential clients can be pre-qualified remotely

and onboarded more thoroughly, and clients can be trained more effectively at scale and at a lower cost on how to get the most from the equipment and maintain it.



Jake Spanswick
CEO

+44 (0)7493 769 997
jspanswick@clearpixelvr.com

<https://clearpixelvr.com/>

Cotton Mouton Diagnostics (CMD) is a south-Wales based SME specialising in the detection of endotoxin in pharmaceutical products.



In addition to launching a new state-of-the-art endotoxin detection system this summer, CMD has established an ISO 17025 (UKAS) accredited Endotoxin Testing Centre that offers endotoxin testing of liquid pharmaceutical products including biopharmaceuticals. Certification covers method development and optimisation as well the provision of low endotoxin recovery studies, making CMD your one-stop-shop for all of your endotoxin testing needs.



Jenna Bowen
Senior Executive Officer

+44 (0)2922 406 366
jbowen@cm-dx.com

www.cm-dx.com

Llusern Scientific has developed a molecular diagnostic analyser for low cost, accurate testing for use in primary, secondary, community and emergency care settings.



The analyser, Lodestar DX, uses LAMP technology to amplify and detect DNA and RNA to identify a wide range of bacterial and viral targets. Lodestar DX has a small footprint, a low manufacturing cost and is suitable for human clinical and veterinary applications.

Llusern's first product is a Urinary Tract Infection (UTI) test panel that tests for the presence of six pathogens in a single microlitre of urine. UTIs are a global healthcare problem with an estimated 150m cases a year. One in two women will get a UTI in their lifetime with elderly patients being a second highly vulnerable patient group. Despite this prevalence there are very few diagnostic tools currently available for UTIs. The need for better diagnosis of UTIs is exacerbated by the need to reduce the volume of antibiotics prescribed for suspected cases in order to counter the impact of antimicrobial resistance (AMR).

AMR is considered to be a healthcare timebomb by the global professional medical community. Llusern's mission is to help reduce the antibiotic burden by improving UTI diagnosis at the point where it is needed most.

Product/Service

Molecular point of care diagnostic tests, primarily for UTIs.

Objectives

1. Market assessment of US for near-patient UTI testing in human and veterinary medicine.
2. Identification of potential commercial partners.
3. Understand US reimbursement for UTI testing, and to meet with insurance providers.
4. Meet with potential platform collaborators.
5. Meetings with potential investors.



Dr Emma Hayhurst
CEO

+44(0)7875 623 910
emma@llusern.co.uk

Martyn Lewis
COO and Head of Commercial

+44 (0)7825 708 936
martyn@llusern.co.uk

www.llusern.co.uk

Sharp is a global leader in pharmaceutical packaging and clinical trial supply services. For 70 years, Sharp has provided solutions to pharma, biotech and MedTech clients from phase I trials through to commercial launch and lifecycle management.



With exceptional, regulatory compliant, facilities in the United States, United Kingdom, Belgium and the Netherlands. Plus 30+ clinical depots globally, covering every region of the world.

Product/Service

Sharp provides multi-phase clinical services and commercial packaging including:

- Formulation development
- Analytical research
- Stability studies
- Sterile Fill Finish
- Clinical manufacturing & packaging
- QP Services
- Interactive Response Technology (IRT)
- Storage & distribution
- Direct-to-Patient
- Return & destruction strategies

Sharp Clinical Services is one of the world's leading providers of innovative packaging supply chain services, with a talented and highly experienced team that handle every aspect of your project management.

Objectives

Sharp is seeking to build on existing client relationships in the USA and meet with new companies to discuss future collaborations.



Rachel Curran
Head of Sourcing Services
& Special Accounts

+44(0)7929 514 210
rachel.curran@sharpclinical.com

Deb Williams
Business Development Manager

+44 (0)7773 036 361
deb.williams@sharpclinical.com

www.sharpservices.com

The Science Behind Limited provides specialist neuroscience technologies and capabilities to sponsors and clinical contract research organizations (CROs) in early-phase clinical trials for neurodegenerative and central nervous system disorders.



The company aims to become the preferred partner for those requiring specialist neuroscience expertise and technology for early-phase clinical trials.

Product/Service

Clinical trials for central nervous system diseases carry a high level of risk, and pharmaceutical companies face significant challenges in developing treatments. The Science Behind's team of neuroscience experts, combined with state-of-the-art technology and techniques, can provide objective and cost-effective methods for measuring drug effects. The company can help questions relating to blood brain barrier penetration, target engagement and dose response. This additional insight can help sponsors make more informed decisions and increase their chances of success in future clinical trials.

Objectives

The Science Behind seeks to meet with sponsors, ideally late-stage preclinical drug development or considering their first-in-human trials, and contract research organizations seeking to build capability to support central nervous system phase I clinical trials.

By working with The Science Behind, pharmaceutical companies can tap into their expertise in neuroscience to overcome the challenges associated with clinical trials for central nervous system diseases, ultimately leading to the development of effective treatments while reducing the risk and costs associated with failed trials.



Tonia Smreczak
Managing Director

+44(0)2922 644 840
tonia@thesciencebehind.com

Soffia Cahill
Research Specialist

+44 (0)2922 644 840
soffia@thesciencebehind.com

www.thesciencebehind.com

Established in 2012 and based in Cardiff, **TrakCel** is the first mover and longest-serving Cellular Orchestration company within the CGT (Cell and Gene Therapy) industry.



Their cloud-based suite of systems offers automated end-to-end tracking of Chain of Identity (COI) and Chain of Custody (COC), currently operational in 100+ sites worldwide.

Supporting 20+ clinical trials and commercial therapies globally, TrakCel stands as the sole Enterprise Orchestration System providing solutions for pre-clinical, clinical, and commercial stages. OCELLOS products are all scalable to accommodate therapy expansion, as well as a diverse array of therapy classes, including Autologous, (CAR-Ts, MILs, TILs), Allogeneic, and Personalized Cancer Vaccines.

This year, they launched TrakCel Consulting Services, leveraging their deep expertise to offer guidance on COI/COC Strategy, Data Protection, Label Design Compliance, Supply Chain Risk Assessment, and SaaS within Pharma.

Product/Service

- OCELLOS** – TrakCel’s flagship product. A cloud-based, fully integrated, end-to-end system that manages global supply chains efficiently, from patient enrollment to infusion. Designed for CGT developers scaling to/at commercialization.
- OCELLOS Lite** – A simplified and preconfigured version of OCELLOS, ideal for those at clinical stage.
- OCELLOS Core** – An initial step into digital COI and COC, designed for pre/early clinical developers.
- TrakCel Consulting Services** – Specialized Cell and Gene Therapy consultancy to help navigate any challenges and optimize internal processes.

Objectives

- Networking:** Engage with key stakeholders, including industry leaders, potential clients, partners, and investors, to expand TrakCel's professional network within the life sciences sector. Prioritize interactions with decision-makers and thought leaders relevant to TrakCel's target market.
- Business Development:** Identify and pursue opportunities for collaboration, partnerships, and client acquisition. Leverage the conference platform to showcase TrakCel's capabilities, solutions, and competitive advantages, with the goal of generating new leads and securing potential business prospects.
- Market Research:** Gather market intelligence, insights, and trends to better understand the evolving landscape of the life sciences industry. Explore emerging technologies, regulatory updates, and market demands to inform TrakCel's product development, marketing strategies, and overall business direction.

—Learning and Development:

Attend workshops, seminars, and educational sessions to enhance knowledge, skills, and competencies relevant to TrakCel's business objectives and industry focus. Stay abreast of the latest advancements, best practices, and regulatory updates to continuously improve TrakCel's offerings and maintain a competitive edge.



Chris Came
Vice President Relationship
Management

+44 (0)7734 365 351
chris.came@trakcel.com

<https://trakcel.com/>

Find out what Wales can do for your business:

Tel: +44 (0) 3000 603000

Web: tradeandinvest.wales

Linked-In: [linkedin.com/showcase/trade-&-invest-wales](https://www.linkedin.com/showcase/trade-&-invest-wales)

Facebook: [facebook.com/InvestWales](https://www.facebook.com/InvestWales)

Instagram: [@InvestWales](https://www.instagram.com/InvestWales)

X: [@InvestWales](https://twitter.com/InvestWales)



Richard Harris

Head of Trade

+44 (0)7891 423 903

richard.harris@gov.wales

Leigh Jacka

Trade Missions & Exhibitions Manager

+44 (0)7814 984 790

leigh.jacka@gov.wales

Overseas Offices – US:

Eoghan O'Regan

Deputy Head of North America

eoghan.oregan@gov.wales



tradeandinvest.wales